January 17, 2025

In vitro chromosomal aberration assay: Unraveling the genetic puzzle to evaluate medical device safety at Labcorp’s Bedford Genetic Toxicology Laboratory

Genotoxicity testing is crucial for medical device safety. Labcorp's chromosomal aberration assay meticulously evaluates chromosomes to determine if a device causes genotoxic harm. This powerful tool assesses potential risks early in development, enabling manufacturers to mitigate risks before commercialization. The scientists at the GeneTox Laboratory in Bedford, Massachusetts, understand the intricacies of this test and offer it to sponsors for the evaluation of their medical devices, one chromosome at a time.
Read more »
January 8, 2025

LABCORP DECLARES QUARTERLY DIVIDEND

BURLINGTON, N.C. , Jan. 8, 2025 /PRNewswire/ --  Labcorp Holdings Inc.  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today that its Board of Directors has declared a cash dividend of $0.72 per share of common stock.
Read more »
<span>Four tips for better health in 2025</span>
January 3, 2025

Four tips for better health in 2025

According to a survey from the American Heart Association, 79% of respondents don’t prioritize their health during the holidays. In fact, they reported having greater stress during the holiday season than during the often-dreaded tax filing period. 
Read more »
February 21, 2022

NASH, NAFLD, & NIS4: Ask an Expert with Marge Connelly

Dr. Margery Connelly is the lead scientist behind several Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) tests at Labcorp, as well as testing for other metabolic disorders. Dr. Connelly discusses the clinical significance of NASH and what positive NASH and liver fibrosis test results mean for patients.
Read more »